A privately-held company developing
Proprietary drug transporter activating technology
For targeted and effective delivery of anticancer drugs
Molecular mimicry technology turning co-administered anti-cancer agents more efficacious, less toxic
Only a small fraction of the administered anti-cancer agent can make it into the tumor. The novel technology of Cend Therapeutics turns the tumor microenvironment into a drug conduit, allowing efficient access of anti-cancer agents deep into the tumor. As a consequence, co-administered anti-cancer agents may become more tumor-targeted, leading to an improved efficacy, as well as an improved safety profile.
The Challenge
Current medications fail to sufficiently penetrate solid tumors.
Technology
Novel technology hijacks body’s own transport system to deliver anti-cancer drugs deep into the tumor.
Key Publications
Clinical-stage molecular mimicry agent validated has been validated in more than 150 publications.